1-3 of 3
John Lambert, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML).

Ollivier Legrand, MD, Maria B. Vidriales, MD, Xavier Thomas, MD, Charles Dumontet, MD, Anne Vekhoff, MD, Rodica Morariu-Zamfir, MD, John Lambert, MD, Jesus F. San Miguel, MD, Jean-Pierre Marie, MD
Journal: Blood
Blood (2007) 110 (11): 1850.
https://doi.org/10.1182/blood.V110.11.1850.1850
Published: 2007
Journal Articles

Phase I Study of AVE9633, an AntiCD33-Maytansinoid Immunoconjugate, Administered as an Intravenous Infusion in Patients with Refractory/Relapsed CD33-Positive Acute Myeloid Leukemia (AML).

Francis Giles, MD, Rodica Morariu-Zamfir, MD, John Lambert, MD, Srdan Verstovsek, MD, Deborah Thomas, MD, Farhad Ravandi, MD, Dan Deangelo, MD
Journal: Blood
Blood (2006) 108 (11): 4548.
https://doi.org/10.1182/blood.V108.11.4548.4548
Published: 2006
Journal Articles

Hematide™, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), Demonstrates Erythropoietic Activity in a Phase 2 Single Dose, Dose Escalating Study in Patients with Chronic Kidney Disease (CKD).

Anne-Marie Duliege, MD, Iain Macdougall, MD, Neill Duncan, MD, Dawie Wessels, MD, Julie Iwashita, Pete Schatz, PhD, Robert Naso, PhD, Richard Stead, MD, John Lambert, MD
Journal: Blood
Blood (2005) 106 (11): 3532.
https://doi.org/10.1182/blood.V106.11.3532.3532
Published: 2005